Advertisement
"Though his work has sometimes been attacked by political and religiousestablishments, Robert Lanza, M.D., forges ahead with research based on theright thing to do scientifically," PharmaVOICE stated. "Dr. Lanza is boldlyleading Advanced Cell Technology's team of scientists toward bringing thebenefits of human embryonic stem cell (hESC) technology to the tens ofmillions of people worldwide who are suffering from a host of degenerativediseases and other conditions," the journal continued. "Committed to thescience, Dr. Lanza believes treatments using hESCs have the potential toeventually offer not just treatments, but actual cures for Parkinson'sdisease, macular degeneration, heart disease, and a whole host of otherdebilitating diseases .... Inspired by enlightened thinkers and humankindness, Dr. Lanza believes in the mission of advancing research, and he islooking forward to the next goal: to start human clinical trials usingembryonic stem cells."
Advertisement
"We are pleased that highly regarded journals such as PharmaVOICE continueto recognize the contributions and achievements of our researchers," remarkedWilliam M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology."Moreover, we are excited by the novel therapies our research may yield totreat indications that have few alternatives."
Over the past year, Advanced Cell Technology has made significant progressin its RPE (retinal pigment epithelium) and its HG (hemangioblast) programs totreat degenerative retinal disorders and cardiovascular disease, and expectsto file INDs for both programs by the end of 2008. Furthermore, the companyannounced last month that it had entered into a definitive merger agreement toacquire autologous adult stem cell company Mytogen, Inc. and its MyoblastProgram for the treatment of heart failure. Mytogen has successfullycompleted Phase I clinical trials and will begin Phase II trials after themerger with ACT. Upon the transaction's closing, Advanced Cell Technologywill transition from a development stage to a clinical stage company.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applyingembryonic stem cell technology in the emerging field of regenerative medicine.The company operates facilities in Alameda, California and Worcester,Massachusetts.
For more information, visit http://www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operatingresults, future growth in research and development programs, potentialapplications of our technology, opportunities for the company and any otherstatements about the future expectations, beliefs, goals, plans, or prospectsexpressed by management constitute forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995. Anystatements that are not statements of historical fact (including statementscontaining the words "will," "believes," "plans," "anticipates," "expects,""estimates," and similar expressions) should also be considered to beforward-looking statements. There are a number of important factors that couldcause actual results or events to differ materially from those indicated bysuch forward-looking statements, including: limited operating history, needfor future capital, risks inherent in the developm
